AAAAAA

   
Results: 1-5 |
Results: 5
Hybritech total and free prostate-specific antigen assays developed for the Beckman Coulter access automated chemiluminescent immunoassay system: A multicenter evaluation of analytical performance
Authors: Laffin, RJ Chan, DW Tanasijevic, MJ Fischer, GA Markus, W Miller, J Matarrese, P Sokoll, LJ Bruzek, DJ Eneman, J Nelson, J Bray, KR Huang, J Loveland, KG
Citation: Rj. Laffin et al., Hybritech total and free prostate-specific antigen assays developed for the Beckman Coulter access automated chemiluminescent immunoassay system: A multicenter evaluation of analytical performance, CLIN CHEM, 47(1), 2001, pp. 129-132
Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging
Authors: Catalona, WJ Southwick, PC Slawin, KM Partin, AW Brawer, MK Flanigan, RC Patel, A Richie, JP Walsh, PC Scardino, PT Lange, PH Gasior, GH Loveland, KG Bray, KR
Citation: Wj. Catalona et al., Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging, UROLOGY, 56(2), 2000, pp. 255-260
Percentage of free PSA in black versus white men for detection and stagingof prostate cancer: A prospective multicenter clinical trial
Authors: Catalona, WJ Partin, AW Slawin, KM Naughton, CK Brawer, MK Flanigan, RC Richie, JP Patel, A Walsh, PC Scardino, PT Lange, PH deKernion, JB Southwick, PC Loveland, KG Parson, RE Gasior, GH
Citation: Wj. Catalona et al., Percentage of free PSA in black versus white men for detection and stagingof prostate cancer: A prospective multicenter clinical trial, UROLOGY, 55(3), 2000, pp. 372-376
Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: A prospective multicenter clinical trial
Authors: Southwick, PC Catalona, WJ Partin, AW Slawin, KM Brawer, MK Flanigan, RC Patel, A Richie, JP Walsh, PC Scardino, PT Lange, PH Gasior, GH Parson, RE Loveland, KG
Citation: Pc. Southwick et al., Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: A prospective multicenter clinical trial, J UROL, 162(4), 1999, pp. 1346-1351
Analytical and clinical performance characteristics of Hybritech's Tandem-R free PSA assay during a large multicenter clinical trial to determine theclinical utility of percentage of free prostate-specific antigen
Authors: Chan, DW Kelley, CA Ratliff, TL D'Agostino, D Ritchey, J Lamb, DJ Beck, J Lott, N Wener, MH Daum, P Henkin, RE Kaske, DN Golightly, DW McBride, J Layco, G Ota, MK Tanasijevic, MJ Grudzien, C Woodrum, DL Bray, KR Southwick, PC Gasior, GH Loveland, KG
Citation: Dw. Chan et al., Analytical and clinical performance characteristics of Hybritech's Tandem-R free PSA assay during a large multicenter clinical trial to determine theclinical utility of percentage of free prostate-specific antigen, CLIN CHEM, 45(10), 1999, pp. 1863-1865
Risultati: 1-5 |